Ny behandling af kronisk hepatitis B
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Ny behandling af kronisk hepatitis B. / Andersen, Ellen Sloth; Weis, Nina M; Weis, Nina M.
In: Ugeskrift for Laeger, Vol. 170, No. 48, 2008, p. 3937-9.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Ny behandling af kronisk hepatitis B
AU - Andersen, Ellen Sloth
AU - Weis, Nina M
AU - Weis, Nina M
PY - 2008
Y1 - 2008
N2 - Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently. Udgivelsesdato: 2008-Nov-24
AB - Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently. Udgivelsesdato: 2008-Nov-24
M3 - Tidsskriftartikel
VL - 170
SP - 3937
EP - 3939
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 48
ER -
ID: 34160162